RxDoctor Payments Data

Khalil Murad, MD

Cardiovascular Disease · Cleveland, OHNPI 1023059425

Payments from drug & device makers

$130,926in general payments, 2019–2025

Across 46 payments — averaging $2846.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • American Regent$131K
  • Abbott$227
  • United Therapeutics Corporation$151
  • Johnson & Johnson$26
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$13

What the payments were for

  • Consulting fees$13031%
  • Food & beverage$26564%
  • Education$215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$130,926 in reported general payments places this provider in the 90th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$33,654
Medicare patients
531
Services billed
812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan97$1,178,674
VyndamaxTafamidis41$910,600
Tyvaso DpiTreprostinil14$353,257
FarxigaDapagliflozin Propanediol342$331,254
EntrestoSacubitril/Valsartan311$302,149
JardianceEmpagliflozin346$293,547
Orenitram ErTreprostinil Diolamine44$160,799
AdempasRiociguat11$155,213
Ambrisentan44$127,027
XareltoRivaroxaban73$81,181
EliquisApixaban44$48,718
Sildenafil Citrate102$33,512
Bumetanide240$9,047
Metoprolol Succinate561$8,941
LokelmaSodium Zirconium Cyclosilicate11$8,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$26$81,18173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →